NEW YORK, Jan. 06, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Arrowhead Pharmaceuticals, Inc. securities (NASDAQ:ARWR) from May 11, 2015 through November 8, 2016, both dates inclusive (the “Class Period”) of the important January 17, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Arrowhead investors under the federal securities laws.
To join the Arrowhead class action, go to http://www.rosenlegal.com/cases-997.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, Defendants made materially false and misleading statements and/or failed to disclose that: (1) ARC-520, one of Arrowhead’s drug candidates for patients with chronic hepatitis B infection, was fatal at certain doses; (2) consequently, the U.S. Food & Drug Administration was unlikely to approve ARC-520 as a hepatitis B treatment; (3) Arrowhead had overstated the approval prospects and commercial viability of ARC-520; and (4) as a result, Arrowhead’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 17, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-997.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Attorney Advertising. Prior results do not guarantee a similar outcome.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com


TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
OpenAI Explores Massive Funding Round at $750 Billion Valuation
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 



